ARTICLE | Emerging Company Profile
Unifying factor in NASH
Why Jecure thinks targeting the inflammasome can address multiple NASH mechanisms
March 2, 2017 7:39 PM UTC
While most companies pursuing NASH are tackling lipid metabolism, immune cell activation or bile acid transport, Jecure Therapeutics Inc. is aiming to treat the disease by blocking activation of the inflammasome, a cellular pathway it thinks drives three intertwining arms of the disease -- hepatocyte injury, innate immunity and fibrosis.
On February 15, Jecure debuted with a $20 million series A round from sole investor Versant Ventures. ...
BCIQ Company Profiles